<DOC>
	<DOCNO>NCT00571935</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate efficacy insulin aspart compare soluble human insulin blood glucose control child 7 year age type 1 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Insulin Aspart MDI CSII Children Below 7 Years Age With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 diabetes least 1 year HbA1c 12.0 % Treatment regular human insulin insulin NPH least 1 month Receive 2 injection daily Receipt investigational product within 6 month prior trial participation Known suspect allergy investigational product Receipt insulin aspart within 3 month prior trial participation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>